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Abstract: This work aimed to investigate and optimise the effects of co-surfactants, hydration
volume, and time on the entrapment of methylene blue (MB) within niosomes and the vesicle
sizes of MB-loaded niosomes upon different storage temperatures. Niosomes were prepared by
the thin film hydration method followed by gel permeation chromatography to obtain purified
niosome suspensions. The probe sonication method was used to reduce the niosome vesicle size
and distribution. Highest entrapment efficiencies (%EE) were determined for niosomal formulations
containing Span® 60, cholesterol, and Cremophor® ELP (E2 and E3), which were prepared with a
hydration volume of 5 mL. The hydration time was 15 min for E2 and 60 min for E3 (%EE = 40.1 ±
7.9% and 32.9 ± 10.1% for E3 and E2, respectively). The final lipid contents in the formulations were
shown to have an impact on %EE.
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1. Introduction
Non-ionic surfactant vesicles (niosomes) are drug carriers that have been extensively studied for
delivering poorly water-soluble drugs to enhance dissolution and bioavailability [1]. To prepare a
hydro-dynamically stable niosome dispersion, vesicle size, lipid content, and compositions are crucial
for vesicle formation and capability retention [2,3].
Usually, cholesterol is used with the main non-ionic surfactant in a 1:1 molar ratio for most
niosomal formulations [4]. Hence, for this current study, Span® 60 and cholesterol were prepared in a
1:1 molar ratio to enable the study’s aim for investigating the effect of process parameters (hydration
time and volume of niosomes) on the niosomes’ characteristics. Methylene blue (MB) was chosen as a
model hydrophilic drug to be encapsulated into the prepared thin film hydrated niosomes.
MB is an antidote agent indicated for drug- or chemical-induced methaemoglobinaemia.
MB-loaded niosomal formulations stabilised by either dicetyl phosphate or Solutol® HS15 were
previously produced by Chaw and Kim [5]. However, this study applied different stabilisers or
co-surfactants (Cremophor® ELP or Lauroglycol® 90).
2. Materials and Methods
The niosomes were prepared by the thin film hydration method. Briefly, a lipid mixture of
Span® 60, cholesterol, and Cremophor® ELP or Lauroglycol® 90 was dissolved in chloroform, and the
solvent was evaporated under reduced pressure (470 mbar) at 60 ◦C using a rotary evaporator (Buchi,
Switzerland). Hydration of the film was performed by adding a Trizma buffer (pH 7.4) containing
methylene blue (Sigma Aldrich, UK) to the round-bottomed flask and the flask was placed in the
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water bath shaker set at 100 rpm and 60 ◦C (refer to Table 1). Purification of niosome suspensions
was carried out using a gel permeation chromatography column made up of Sephadex G50 (Sigma
Aldrich, UK). The eluted niosomes were collected and disrupted using isopropanol to determine the
concentration of MB using a UV–Vis visible spectrophotometer (Camspec, UK) at a wavelength of
665 nm as well as using the constructed calibration curve of MB. Vesicle sizes and size distributions
of the prepared niosome dispersions were measured by a nanosize instrument (Malvern, UK) before
and after probe sonication (Cole Parmer, UK) applied with an amplitude set at 40% for two cycles of
two minutes each with a minute rest in between. During the sonication process, samples were placed
in an ice bath to prevent overheating. This was followed by centrifugation (MSE, UK) at 5000 rpm
for 5 min to remove any impurities. The vesicle sizes of the niosomes before probe sonication at two
different storage temperatures (fridge, 4 ◦C; and room temperature, 23 ◦C) were determined weekly
for a period of four weeks.
Table 1. Hydration volume (mL), hydration time (min), niosome size (nm) pre-sonication and

















S60: Cho: ELP b 20 60 804.0 ± 294.8 272.9 ± 105.1 0.56 ± 0.28 0.39 ± 0.24
E2
S60: Cho: ELP b 5 15 1514.3 ± 203.5 292.4 ± 12.3 0.40 ± 0.17 0.38 ± 0.23
E3
S60: Cho: ELP b 5 60 615.7 ± 126.8 362.2 ± 138.3 0.71 ± 0.25 0.45 ± 0.17
E4
S60: Cho: ELP b 2.5 60 619.7 ± 191.2 311.7 ± 27.4 0.72 ± 0.16 0.36 c 0.16
L1
S60: Cho: L90 b 5 60 1463.4 ± 62.4 256.9 ± 51.9 0.46 ± 0.06 0.34 ± 0.13
For all experiments, results were the average of triplicates from three prepared lots (n = 3) ± standard deviation.
a All formulations E1, E2, E3, E4, and L1 were prepared at a molar ratio of 45:45:10. b Span® 60 (S60); cholesterol
(Cho); Cremophor® ELP (ELP); Lauroglycol® 90 (L90).
Morphologies of MB-loaded niosomes were characterised by transmission electron microscopy
(Hitachi, UK). A negative staining procedure was performed using a 2% aqueous phosphotungstic
acid (PTA) reagent. Figure 1, which shows TEM photomicrographs, indicated that niosomes had
vesicular/spherical shapes, with methylene blue in the hydrophilic cores of the prepared niosomes.
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the lipophilic Lauroglycol® 90 could be competing with cholesterol in the bilayer membranes of the 
niosomes. Furthermore, the overall HLB for L1 is smaller compared with other formulations, and 
hence it has no compatibility with water-soluble MB. Therefore, further research may be carried out 
using Lauroglycol® 90 as a co-surfactant.  
All purified formulations revealed a high polydispersity index of above 0.4, indicating non-
homogeneity in size distributions before probe sonication. After probe sonication, vesicles 
Figure 1. Transmission electron microscopy (TEM) images of formulations E1 (top, A) and E2 (below,
B) before sonication.
3. Results and Discussion
For the prepared niosomes, hydration for relatively short hydration time (15 min, E2) produced
vesicles (before the sonication step) with larger sizes an slightly less drug entrapment efficiency
compared to niosomes hydrated for a longer period of hydration (60 min, E3). This suggests that
60 min is an optimum time for the f ll ydr tion of polar heads of the used Span® 60 and for the
formation of vesicula spherical shapes (Table 1; Figure 1). Longer hydration time contributed to
reduced vesicle size in niosomes despite different hydration volumes. However, with a constant total
initial lipid mass (200 mg) used, the increasing final lipid concentration with decreasing hydration
volumes resulted in a noticeable in re s in %EE from E1 (22.1%) to E3 (40.1%), followed by a decrease
in %EE from E3 (40.1%) to E4 (27.9%) (Tables 1 and 2). These results concluded that a higher final lipid
content (80 mg/mL) mi ht contribute to a saturated environment where the successful formation of
vesicles is prevented. Additionally, this esult corre ponded to the v sicle sizes of niosomes (Table 1).






Before Sonication After Sonication
E1
S60: Cho: ELP b 10 22.1 ± 12.7 14.3 ± 1.3
E2
S60: Cho: ELP b 40 32.9 ± 10.1 16.3 ± 3.5
E3
S60: Cho: ELP b 40 40.1 ± 7.9 11.6 ± 4.5
E4
S60: Cho: ELP b 80 27.9 ± 15.8 18.0 ± 14.5
L1
S60: Cho: L90 b 40 10.5 ± 2.4 27.1 ± 1.4
For all experiments, n = 3. a All formulations E1, E2, E3, E4, and L1 were prepared at a molar ratio of 45:45:10.
b Span® 60 (S60); cholesterol (Cho); Cremophor® ELP (ELP); Lauroglycol® 90 (L90).
In comparison with using non-ionic water-soluble surfactant (Cremophor® ELP, HLB (Hydrophilic
Lipophilic Balance) value of 12–14), L1 with incorporation of non-ionic water-insoluble surfactant
(Lauroglycol® 90, HLB value of 3) demonstrated an increase in vesicle size but a decrease in %EE
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before sonication (Tables 1 and 2). The results might be explained by the low loading and leaking of
MB from the large vesicle size due to the weak membrane rigidity, as it is expected that the lipophilic
Lauroglycol® 90 could be competing with cholesterol in the bilayer membranes of the niosomes.
Furthermore, the overall HLB for L1 is smaller compared with other formulations, and hence it
has no compatibility with water-soluble MB. Therefore, further research may be carried out using
Lauroglycol® 90 as a co-surfactant.
All purified formulations revealed a high polydispersity index of above 0.4, indicating
non-homogeneity in size distributions before probe sonication. After probe sonication, vesicles
demonstrated marked reductions in size and size distribution (Table 1), showing the effectiveness of
probe sonication for producing niosomes of higher homogeneity.
Reduced vesicle size was attributed to longer hydration time. Final lipid contents in the vesicular
system at 40 mg/mL demonstrated the highest %EE (Table 2). By including a probe sonication process,
the sizes of non-homogenous niosome dispersions were effectively reduced, and sonication led to the
formation of homogeneous niosomes.
The stability of niosomes at different storage temperatures was assessed by changes in vesicle size
(in pre-sonicated states) over time. Under fridge conditions (4 ± 2 ◦C), L1 niosomes showed a slight
increase in size and E2 niosomes demonstrated a large variation in size over storage (Figure 2). In
contrast, large fluctuations in size can be seen upon room temperature storage (23 ± 2 ◦C) in both E2
and L1 niosome formulations. Generally, prepared formulations which demonstrated smaller vesicle
sizes revealed slight variations regardless of the different storage temperatures, with E1 showing the
least variation in size.
Pharmaceuticals 2019, 12, x 5 of 6 
 
demonstrated marked reductions in size and size distribution (Table 1), showing the effectiveness of 
probe sonication for producing niosomes of higher homogeneity. 
Reduced vesicle size was attributed to longer hydration time. Final lipid contents in the vesicular 
system at 40 mg/mL demonstrated the highest %EE (Table 2). By including a probe sonication 
process, the sizes of non-homogenous nios me dispersions were effectively reduced, and soni tion 
led to the formation of homogeneous niosomes.  
The stability of niosomes at different storage temperatures was assessed by changes in vesicle 
size (in pre-sonicated states) over time. Under fridge conditions (4 ± 2 °C), L1 niosomes showed a 
slight increase in size and E2 niosomes demonstrated a large variation in size over storage (Figure 2). 
In contrast, larg  fluctuations in size can be seen upon room temperature storage (23 ± 2 °C) i  both 
E2 and L1 niosome formulations. Generally, prepared formulations which demonstrated smaller 
vesicle sizes revealed slight variations regardless of the different storage temperatures, with E1 
showing the least variation in size. 
Based on Figure 2, E3 was more stable compared to E2. E1 confirmed the results of E3 regarding 
good stability from using a hydration time of 60 mi . E4 showed poor stability, having a high lipid 
content (Figure 2). L1 confirmed the E2 results of large vesicle sizes remaining the same after storage.  
4. Conclusion 
The results of this study showed that the E3 formula with Cremophor® ELP co-surfactant, 60 
min hydration time, and 5 mL hydration volume produced stable niosomes with optimal lipid 
content for optimal MB encapsulation efficiency. The vesicle size influenced the formulation stability.  
 
Figure 2. Niosome size measurements of all formulations (before probe sonication) kept under fridge 
(4 ± 2 °C) and room temperature (23 ± 2 °C) conditions over a four-week period. 
References 
1. Marianecci, C., Di Marzio, L., Rinaldi, F., Celia, C., Paolino, D., Alhaique, F., Esposito, S., Carafa, M. 
Niosomes from 80s to present: The state of the art. Adv Colloid Interface Sci. 2014, 205, 187–206. 
Figure 2. Niosome size measurements of all for ulations (before probe sonication) kept under fridge
(4 ± 2 ◦C) and room temperature (23 ± 2 ◦C) conditions over a four-week period.
Based on Figure 2, E3 was more stable compared to E2. E1 confirmed the results of E3 regarding
good stability from using a hydration time of 60 min. E4 showed poor stability, having a high lipid
content (Figure 2). L1 confirmed the E2 results of large vesicle sizes remaining the same after storage.
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4. Conclusions
The results of this study showed that the E3 formula with Cremophor® ELP co-surfactant, 60 min
hydration time, and 5 mL hydration volume produced stable niosomes with optimal lipid content for
optimal MB encapsulation efficiency. The vesicle size influenced the formulation stability.
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